Acelyrin, Poison Pill and Tang Capital
Acelyrin Adopts Poison Pill as Tang Capital Partners Builds Stake
The late-stage biopharma said the plan will issue one right for each share of common stock as of the close of business on March 24. The rights will initially trade with its common stock, and will become exercisable only if any person acquires 10% or more of Acelyrin's outstanding common stock.
Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...
ACELYRIN (SLRN) announced that, in response to Tang Capital Partners’ continued rapid accumulation of 8.8% of ACELYRIN’S outstanding common ...
Los Angeles-based Acelyrin consulted with independent financial and legal advisors and came to the conclusion that the unsolicited interest from Tang Capital Partners-owned Concentra was “not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback